相关临床试验
23
18 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
18
78.3%
已完成
2
8.7%
招募中
2
8.7%
终止
1
4.3%
暂无批准数据
- Long-term results from the Optimum (MUK Nine) trial show 70% of high-risk myeloma patients on personalised treatment were alive at six years, versus around 40% on standard therapy. - Progression-free survival at six years reached 54% with the risk-adapted approach, compared with 18% for patients receiving usual care. - The trial, led by The Institute of Cancer Research, combined a stem cell transplant with five existing NHS drugs, adapted to each patient's molecular disease biology. - Researchers found the MMProfiler SKY92 gene-expression test identifies high-risk patients who are currently missed, and it is now under regulatory evaluation for NHS use.
- The BLAZE Phase 1/2 trial has updated its anti-PD-1 combination backbone to nivolumab (Opdivo®) and is advancing toward first patient enrollment in checkpoint-resistant NSCLC and melanoma. - The BEXAR randomized Phase 1b/2 trial received regulatory approval to evaluate bexmarilimab plus doxorubicin in first-line metastatic soft-tissue sarcoma, a tumor type with among the highest Clever-1 expression. - The proposed bexmarilimab cohort in the FINPROVE platform trial was deemed incompatible by Finnish regulators (Fimea) and will not proceed, though this does not affect the broader development program. - Two additional IITs in hematological malignancies — BEAM-X in MRD-positive AML and a City of Hope-sponsored trial in r/r MDS — continue advancing through protocol development.
- Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025 to advance its Phase 2 OCTOPOD-IV clinical trial of THEO-260 in platinum-resistant ovarian cancer. - THEO-260 is a novel oncolytic immunotherapy designed to kill both cancer cells and cancer-associated fibroblasts while inducing immune activation in stroma-rich solid tumors. - The competitive funding award validates the company's innovative approach to addressing significant unmet medical needs in patients with advanced ovarian cancer, whose life expectancy is typically one year or less. - The grant will support up to 20 patients in the Phase 2a expansion study and involves major international clinical centers including institutions in Spain, Canada, and the UK.
- Faron Pharmaceuticals has initiated the Phase I/II BLAZE trial in collaboration with The Institute of Cancer Research to test bexmarilimab combined with zimberelimab in patients with metastatic NSCLC and melanoma who developed resistance to anti-PD-1 therapy. - The trial employs a novel sequential approach, first priming patients with bexmarilimab monotherapy to reprogram tumor-associated macrophages, then adding zimberelimab to resensitize tumors to checkpoint inhibitor treatment. - The study addresses a critical unmet need, as the majority of patients with advanced melanoma and lung cancer eventually develop resistance to first-line anti-PD-1 immunotherapy, with very limited effective subsequent treatment options. - Success in this trial could pave the way for broader applications of macrophage-targeted therapies in solid tumors and potentially make 'cold' tumors sensitive to checkpoint inhibitors.
- Researchers at The Institute of Cancer Research mapped 12 CRBN gene mutations in myeloma cells, revealing that not all mutations equally block immunomodulatory drug effectiveness. - The study found three distinct patterns: some mutations completely disable drug activity, others have no impact, and a third group blocks older IMiDs while allowing newer CELMoDs to remain effective. - Findings suggest clinicians can use mutation-specific data to select appropriate therapies rather than ruling out entire drug classes based on CRBN mutations. - Up to one-third of myeloma patients who develop resistance to IMiD drugs acquire CRBN gene mutations, making this research clinically significant for treatment decisions.
- Researchers at The Institute of Cancer Research, London have developed two innovative blood tests that can guide breast cancer treatment decisions without requiring invasive tissue biopsies. - The Breast Circulating Methylation Assay (BCMA) can identify different breast cancer subtypes with nearly 90% accuracy and detect when tumors switch types during treatment. - A separate circulating tumor DNA test can predict treatment response, showing that patients with low ctDNA levels had significantly longer progression-free survival compared to those with higher levels. - These liquid biopsies could transform breast cancer care by enabling faster, more personalized treatment decisions and avoiding ineffective therapies.
- The UK National Screening Committee has recommended targeted prostate cancer screening only for men with BRCA1 or BRCA2 gene variants, conducted every two years between ages 45-61. - The recommendation excludes Black men and those with family history but no BRCA mutations, despite these groups having elevated prostate cancer risk. - A 23-year European study showed PSA screening reduced prostate cancer mortality by 13%, preventing 22 deaths per 10,000 men screened. - The TRANSFORM clinical trial has launched to provide evidence on broader screening approaches, including for higher-risk populations currently excluded from the recommendation.
- Two major clinical trials presented at ASTRO 2025 reached opposite conclusions about proton beam therapy's effectiveness compared to intensity-modulated radiotherapy (IMRT) for head and neck cancer treatment. - The UK's TORPEdO trial found no significant differences in side effects between proton beam therapy and IMRT in 205 patients, with both treatments showing similar outcomes for taste, swallowing, and quality of life measures. - Memorial Sloan Kettering's phase 2 trial demonstrated that proton beam therapy significantly reduced acute mucositis (7.5% vs 22.2%) and taste dysfunction while maintaining comparable survival rates in 98 patients. - Both studies achieved similar three-year survival rates exceeding 90%, but differed in their assessment of treatment-related toxicities and patient-reported quality of life outcomes.
- Researchers at St. Jude Children's Research Hospital have developed a breakthrough combination therapy using indisulam, a molecular glue drug, with anti-GD2 immunotherapy that achieved complete tumor eradication in preclinical neuroblastoma models. - The study, published in Nature Communications, reveals that neuroblastoma cells exhibit more complex plasticity than previously understood, with multidirectional state transitions that enable resistance to single-targeted therapies. - The combination approach exploits indisulam's dual mechanism of disrupting RNA splicing through RBM39 degradation while simultaneously activating natural killer cells and enhancing GD2 expression for improved immunotherapy effectiveness. - This therapeutic strategy addresses a critical unmet need in high-risk neuroblastoma, where nearly half of patients face aggressive treatments with substantial toxicity and relapse rates approaching 50%.
- Researchers at Augusta University discovered that combining beta-blockers with oncolytic herpes simplex virus significantly improves breast cancer treatment by blocking tumor's protective mechanisms and reprogramming immune cells. - Scientists at The Institute of Cancer Research demonstrated that pairing reovirus with targeted drugs talazoparib and palbociclib dramatically boosts immune responses and cancer cell death in laboratory and mouse studies. - Both studies reveal how tumors manipulate the body's stress responses and immune systems to resist treatment, offering new strategies for more effective personalized cancer therapies. - The combination approaches not only enhance immediate tumor destruction but also help train the immune system to develop memory against cancer recurrence.
